热毒宁注射液联合哌拉西林／舒巴坦钠治疗社区获得性肺炎疗效观察

Efficacy of Reduning injection combined with piperacillin sulbactam in the treatment of community acquired pneumonia

目的：观察热毒宁注射液联合哌拉西林钠／舒巴坦钠治疗社区获得性肺炎（CAP）的临床疗效及安全性。方法将临床确诊为 CAP 的122例患者按数字表法随机分为治疗组和对照组，两组分别常规使用哌拉西林钠／舒巴坦钠3．75 g，每12小时一次，疗程7～10 d，治疗组加用热毒宁注射液，20 mL／d，疗程7～10 d，观察两组治疗前后的临床症状症状缓解时间、白细胞总数（WBC）及 CRP 恢复正常时间。结果治疗组有效率为94．91％，对照组为80．00％，两组差异有统计学意义（χ2＝10．286，P ＜0.05）；治疗组在控制发热、咳嗽症状缓解时间方面明显短于对照组（均 P ＜0．05）；两组治疗后3个月内 WBC 及 CRP 恢复正常率比较差异有统计学意义（χ2＝2．880，3．926，均 P ＜0．05）；两组均未见明显的毒副作用与不良反应。结论热毒宁注射液联合哌拉西林钠／舒巴坦钠治疗 CAP 可协同退热、缓解临床症状症状，临床疗效及安全性好，可作为 CAP 的有效治疗方法之一。

Objective To observe the clinical efficacy and safety of Reduning injection combined with pip-eracillin sulbactam in the treatment of community acquired pneumonia（CAP）.Methods 122 cases with CAP were randomly divided into treatment group and control group by digital table method.The two groups were given piperacil-lin sodium and sulbactam sodium 3.75g,once every 12 hours,course 7 -10d.The treatment group was treated with Reduning injection,20ml/d treatment for 7 -10d.The clinical symptoms of the two groups before and after treatment, the total number of white blood cells（WBC）and C reactive protein（CRP）to resume normal time were observed. Results The effective rate was 94.91% in the treatment group and 80% in the control group,the difference between the two groups was statistically significant（χ2 =10.286,P〈0.05）.The treatment group was significantly shorter than the control group in controlling fever and cough symptoms（all P〈0.05）.3 months after treatment,the WBC and CRP recovery to the normal rate of the two groups had statistically significant differences （χ2 =2.880,3.926,all P〈0.05）.No obvious toxic side effects and adverse reactions were observed in the two groups.Conclusion Reduning injection combined with piperacillin sodium and sulbactam sodium in the treatment of CAP can alleviate the clinical symptoms of fever.This method has good clinical curative effect and high safety.It can be used as an effective method for treatment of CAP.